Associate Professor
Dana-Farber and Children's Hospital
Katherine Janeway, MD, MMSc is Senior Physician in pediatric oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. She is an expert in caring for children, adolescents and young adults with sarcomas. Dr. Janeway’s research is focused on genomics, precision oncology and bone sarcomas. She leads clinical trials in osteosarcoma and Ewing sarcoma both as an independent investigator and as the Chair of the Children’s Oncology Group’s (COG) Bone Tumor Committee.
Dr. Janeway’s work has uncovered the genomic events causing and sustaining difficult to treat childhood solid malignancies. She has leveraged this understanding to expand treatment opportunities and improve clinical trials for these children. She is part of the leadership team of the only national precision oncology trial in children to be conducted in the United States, the National Cancer Institute-COG Pediatric MATCH trial. Dr. Janeway took on the role of Director of Clinical Genomics at Dana-Farber Cancer Institute in 2018.
Dr. Janeway’s research group is currently focused on better characterizing the clinical impact of genomic sequencing. She leads the 12-institution iCat2/GAIN consortium study which has enrolled and sequenced over 500 patients with rare, difficult to treat childhood solid cancers. Her group is also contributing to efforts, as part of the National Cancer Institute’s Childhood Cancer Data Initiative, to share and aggregate both sequencing and clinical data to enable a deeper understanding of clinicogenomic factors explaining prognosis and treatment response and resistance in childhood cancers. Finally, in collaboration with Dr. Wagle from the Broad Institute and Count Me In, Dr. Janeway is innovating patient partnerships in sarcoma research.